- call +1-201-465-4211
- email sales@mrinsights.biz
Glaucoma is chronic, degenerative disorder that damages the eye's optic nerve, may result in vision loss and blindness. Factors such, high prevalence of glaucoma, technological advancement in diagnostic technique, rising treatment awareness are driving the market growth of glaucoma therapeutics globally.
Scope of the Report:
This report studies the Glaucoma Therapeutics market status and outlook of Global and major regions, from angles of players, countries, product types and end industries; this report analyzes the top players in global market, and splits the Glaucoma Therapeutics market by product type and applications/end industries.
The change in the lifestyle of people has resulted in the rise in the prevalence of glaucoma globally. Increasing prevalence of glaucoma is the primary factor driving the growth of glaucoma therapeutics market around the globe. Glaucoma is more prevalent among the people above the age of 60. Rising geriatric population thought the globe is also responsible for the robust growth of glaucoma therapeutics market over the forecast period. Increasing preference of physician towards the laser surgery for the treatment of glaucoma will propel the growth of glaucoma therapeutics market over the forecast period. Less awareness among the people about the glaucoma treatment will deter the growth of glaucoma therapeutics market to some extent. Moreover, lack of availability of skilled professional for laser surgery in under developing economies will also hamper the growth of glaucoma therapeutics market.
The consumption of glaucoma drugs in the Americas is increasing due to the rising incidence of glaucoma in countries such as the US. Owing to its heavy investments in the healthcare sector, the US the major revenue contributor to the glaucoma therapeutics market in this region. With the presence of pharmaceutical giants and huge investments in the pharmaceutical industry, the need for glaucoma therapeutics will increase in the region during the predicted period.
The global Glaucoma Therapeutics market is valued at xx million USD in 2017 and is expected to reach xx million USD by the end of 2023, growing at a CAGR of xx% between 2017 and 2023.
The Asia-Pacific will occupy for more market share in following years, especially in China, also fast growing India and Southeast Asia regions.
North America, especially The United States, will still play an important role which cannot be ignored. Any changes from United States might affect the development trend of Glaucoma Therapeutics.
Europe also play important roles in global market, with market size of xx million USD in 2017 and will be xx million USD in 2023, with a CAGR of xx%.
Market Segment by Companies, this report covers
Allergan
Pfizer
Novartis
Merck
Market Segment by Regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, Colombia)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Market Segment by Type, covers
Prostaglandin Analogs
Beta Blockers
Alpha Agonists
Carbonic Anhydrase Inhibitors
Market Segment by Applications, can be divided into
Ophthalmic Clinic
Hospitals
Ambulatory Surgical Centers
The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.
Market is segmented on the basis:
The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.
The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.
Table of Contents
1 Glaucoma Therapeutics Market Overview
1.1 Product Overview and Scope of Glaucoma Therapeutics
1.2 Classification of Glaucoma Therapeutics by Types
1.2.1 Global Glaucoma Therapeutics Revenue Comparison by Types (2017-2023)
1.2.2 Global Glaucoma Therapeutics Revenue Market Share by Types in 2017
1.2.3 Prostaglandin Analogs
1.2.4 Beta Blockers
1.2.5 Alpha Agonists
1.2.6 Carbonic Anhydrase Inhibitors
1.3 Global Glaucoma Therapeutics Market by Application
1.3.1 Global Glaucoma Therapeutics Market Size and Market Share Comparison by Applications (2013-2023)
1.3.2 Ophthalmic Clinic
1.3.3 Hospitals
1.3.4 Ambulatory Surgical Centers
1.4 Global Glaucoma Therapeutics Market by Regions
1.4.1 Global Glaucoma Therapeutics Market Size (Million USD) Comparison by Regions (2013-2023)
1.4.1 North America (USA, Canada and Mexico) Glaucoma Therapeutics Status and Prospect (2013-2023)
1.4.2 Europe (Germany, France, UK, Russia and Italy) Glaucoma Therapeutics Status and Prospect (2013-2023)
1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia) Glaucoma Therapeutics Status and Prospect (2013-2023)
1.4.4 South America (Brazil, Argentina, Colombia) Glaucoma Therapeutics Status and Prospect (2013-2023)
1.4.5 Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa) Glaucoma Therapeutics Status and Prospect (2013-2023)
1.5 Global Market Size of Glaucoma Therapeutics (2013-2023)
2 Manufacturers Profiles
2.1 Allergan
2.1.1 Business Overview
2.1.2 Glaucoma Therapeutics Type and Applications
2.1.2.1 Product A
2.1.2.2 Product B
2.1.3 Allergan Glaucoma Therapeutics Revenue, Gross Margin and Market Share (2016-2017)
2.2 Pfizer
2.2.1 Business Overview
2.2.2 Glaucoma Therapeutics Type and Applications
2.2.2.1 Product A
2.2.2.2 Product B
2.2.3 Pfizer Glaucoma Therapeutics Revenue, Gross Margin and Market Share (2016-2017)
2.3 Novartis
2.3.1 Business Overview
2.3.2 Glaucoma Therapeutics Type and Applications
2.3.2.1 Product A
2.3.2.2 Product B
2.3.3 Novartis Glaucoma Therapeutics Revenue, Gross Margin and Market Share (2016-2017)
2.4 Merck
2.4.1 Business Overview
2.4.2 Glaucoma Therapeutics Type and Applications
2.4.2.1 Product A
2.4.2.2 Product B
2.4.3 Merck Glaucoma Therapeutics Revenue, Gross Margin and Market Share (2016-2017)
3 Global Glaucoma Therapeutics Market Competition, by Players
3.1 Global Glaucoma Therapeutics Revenue and Share by Players (2013-2018)
3.2 Market Concentration Rate
3.2.1 Top 5 Glaucoma Therapeutics Players Market Share
3.2.2 Top 10 Glaucoma Therapeutics Players Market Share
3.3 Market Competition Trend
4 Global Glaucoma Therapeutics Market Size by Regions
4.1 Global Glaucoma Therapeutics Revenue and Market Share by Regions
4.2 North America Glaucoma Therapeutics Revenue and Growth Rate (2013-2018)
4.3 Europe Glaucoma Therapeutics Revenue and Growth Rate (2013-2018)
4.4 Asia-Pacific Glaucoma Therapeutics Revenue and Growth Rate (2013-2018)
4.5 South America Glaucoma Therapeutics Revenue and Growth Rate (2013-2018)
4.6 Middle East and Africa Glaucoma Therapeutics Revenue and Growth Rate (2013-2018)
5 North America Glaucoma Therapeutics Revenue by Countries
5.1 North America Glaucoma Therapeutics Revenue by Countries (2013-2018)
5.2 USA Glaucoma Therapeutics Revenue and Growth Rate (2013-2018)
5.3 Canada Glaucoma Therapeutics Revenue and Growth Rate (2013-2018)
5.4 Mexico Glaucoma Therapeutics Revenue and Growth Rate (2013-2018)
6 Europe Glaucoma Therapeutics Revenue by Countries
6.1 Europe Glaucoma Therapeutics Revenue by Countries (2013-2018)
6.2 Germany Glaucoma Therapeutics Revenue and Growth Rate (2013-2018)
6.3 UK Glaucoma Therapeutics Revenue and Growth Rate (2013-2018)
6.4 France Glaucoma Therapeutics Revenue and Growth Rate (2013-2018)
6.5 Russia Glaucoma Therapeutics Revenue and Growth Rate (2013-2018)
6.6 Italy Glaucoma Therapeutics Revenue and Growth Rate (2013-2018)
7 Asia-Pacific Glaucoma Therapeutics Revenue by Countries
7.1 Asia-Pacific Glaucoma Therapeutics Revenue by Countries (2013-2018)
7.2 China Glaucoma Therapeutics Revenue and Growth Rate (2013-2018)
7.3 Japan Glaucoma Therapeutics Revenue and Growth Rate (2013-2018)
7.4 Korea Glaucoma Therapeutics Revenue and Growth Rate (2013-2018)
7.5 India Glaucoma Therapeutics Revenue and Growth Rate (2013-2018)
7.6 Southeast Asia Glaucoma Therapeutics Revenue and Growth Rate (2013-2018)
8 South America Glaucoma Therapeutics Revenue by Countries
8.1 South America Glaucoma Therapeutics Revenue by Countries (2013-2018)
8.2 Brazil Glaucoma Therapeutics Revenue and Growth Rate (2013-2018)
8.3 Argentina Glaucoma Therapeutics Revenue and Growth Rate (2013-2018)
8.4 Colombia Glaucoma Therapeutics Revenue and Growth Rate (2013-2018)
9 Middle East and Africa Revenue Glaucoma Therapeutics by Countries
9.1 Middle East and Africa Glaucoma Therapeutics Revenue by Countries (2013-2018)
9.2 Saudi Arabia Glaucoma Therapeutics Revenue and Growth Rate (2013-2018)
9.3 UAE Glaucoma Therapeutics Revenue and Growth Rate (2013-2018)
9.4 Egypt Glaucoma Therapeutics Revenue and Growth Rate (2013-2018)
9.5 Nigeria Glaucoma Therapeutics Revenue and Growth Rate (2013-2018)
9.6 South Africa Glaucoma Therapeutics Revenue and Growth Rate (2013-2018)
10 Global Glaucoma Therapeutics Market Segment by Type
10.1 Global Glaucoma Therapeutics Revenue and Market Share by Type (2013-2018)
10.2 Global Glaucoma Therapeutics Market Forecast by Type (2018-2023)
10.3 Prostaglandin Analogs Revenue Growth Rate (2013-2023)
10.4 Beta Blockers Revenue Growth Rate (2013-2023)
10.5 Alpha Agonists Revenue Growth Rate (2013-2023)
10.6 Carbonic Anhydrase Inhibitors Revenue Growth Rate (2013-2023)
11 Global Glaucoma Therapeutics Market Segment by Application
11.1 Global Glaucoma Therapeutics Revenue Market Share by Application (2013-2018)
11.2 Glaucoma Therapeutics Market Forecast by Application (2018-2023)
11.3 Ophthalmic Clinic Revenue Growth (2013-2018)
11.4 Hospitals Revenue Growth (2013-2018)
11.5 Ambulatory Surgical Centers Revenue Growth (2013-2018)
12 Global Glaucoma Therapeutics Market Size Forecast (2018-2023)
12.1 Global Glaucoma Therapeutics Market Size Forecast (2018-2023)
12.2 Global Glaucoma Therapeutics Market Forecast by Regions (2018-2023)
12.3 North America Glaucoma Therapeutics Revenue Market Forecast (2018-2023)
12.4 Europe Glaucoma Therapeutics Revenue Market Forecast (2018-2023)
12.5 Asia-Pacific Glaucoma Therapeutics Revenue Market Forecast (2018-2023)
12.6 South America Glaucoma Therapeutics Revenue Market Forecast (2018-2023)
12.7 Middle East and Africa Glaucoma Therapeutics Revenue Market Forecast (2018-2023)
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Data Source
List of Tables and Figures
Figure Glaucoma Therapeutics Picture
Table Product Specifications of Glaucoma Therapeutics
Table Global Glaucoma Therapeutics and Revenue (Million USD) Market Split by Prod
ProactiveWe manage our resources 24/7 to identify issues and address them before they become problems
Quality & ReliabilityWe are committed to providing reliable and highly accurate data with an excellent quality control system
Global Outreach6 Major regions and 40+ countries level analysis accomplished
Competitive PricingOur pricing strategy is highly competitive in the market, without compensating on the quality and the timeline of project delivery
